Review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial

1,573 views

Published on

Published in: Health & Medicine, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,573
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
27
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial

  1. 1. Review update of Trilipix (fenofibric acid) and the ACCORD Lipid trialNicolas BERNARDFlorent ZOONEKYND December 2nd,2011
  2. 2. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM258120.pdf
  3. 3. Action via PPARα :  Increase lipoprotein liposis  Stimulation of β-oxydation  Increase removal of LDL particules  Increase HDL productionPharmacological consequences :  Reduce TG  Increase HDL-C  Variable effects on LDL-C
  4. 4.  ACCORD = Action to Control Cardiovascular Risk in Diabetes Study began in 2001 and took place in 77 clinical sites across United States and Canada. Three clinical trials, which tested different treatment approaches to determine the best ways to decrease the high rate of major CVD events in patients with type 2 diabetes : •ACCORD blood sugar trials •ACCORD blood pressure trials •ACCORD lipids trials http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q_a.htm#questions
  5. 5.  Fenofibrate + simvastatin VS simvastatin + placebo 5518 patients with modest degree of dyslipidemia(2765 randomized to fenofibrate) Primary Outcome: First occurrence of a major cardiovascular event (nonfatal MI, nonfatal stroke, cardiovascular death) Mean duration of follow up was 4.7 years
  6. 6. http://www.nejm.org/doi/full/10.1056/NEJMoa1001282#t=articleResults
  7. 7. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM258121.pdf
  8. 8. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM258120.pdf
  9. 9.  FDA is requiring the manufacturer of Trilipix to conduct a clinical trial to test the hypothesis that Trilipix in combination with a statin versus statin alone significantly reduces the incidence of major adverse cardiovascular events in high-risk men and women who are at their LDL cholesterol goal on statin therapy, but have residually high triglycerides and low HDL cholesterol.
  10. 10.  Additional Information for Patients ◦ Trilipix has not been shown to lower patients risk of having a heart attack or a stroke. ◦ Patients should not stop taking their Trilipix medicine without first consulting with their healthcare professional. ◦ Patients should discuss the benefits and risks of taking Trilipix with their healthcare professional. ◦ Patients should read the Medication Guide that they get along with their Trilipix prescription. ◦ Patients should talk to their healthcare professional if they have any questions or concerns about Trilipix. ◦ Patients should report serious side effects from the use of Trilipix to the FDA MedWatch program, using the information in the "Contact Us" box at the bottom of this page.
  11. 11.  Additional Information for Healthcare Professionals ◦ Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in patients in two large randomized controlled trials of patients with type 2 diabetes mellitus. ◦ Healthcare professionals should consider the benefits and risks of Trilipix when deciding to prescribe the drug to patients, and counsel patients about those benefits and risks. ◦ Healthcare professionals should encourage patients to read the Medication Guide they receive along with their Trilipix prescription. ◦ Healthcare professionals should report adverse events involving Trilipix to the FDA MedWatch program using the information in the "Contact Us" box at the bottom of this page.
  12. 12. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089806.pdf

×